Wegovy patent expiration?

Wegovy’s active ingredient is semaglutide (a GLP‑1 receptor agonist). Whether you’re asking about “Wegovy” specifically or the underlying semaglutide patents, the answer depends on which patent(s) and which country you mean.

Quick, practical overview (US + EU)

• US (FDA market exclusivity / patent landscape): The key “patent expiration” story for Wegovy is tied to the semaglutide drug substance and to specific formulations and dosing/device-related patents, plus regulatory exclusivity terms. Even after some patents expire, other patents can block generic or biosimilar competition for certain claims.
• EU/UK: Similar—there are multiple layers: patent expiry dates vary by claim, and regulator exclusivity can extend market protection beyond the first patent that expires.

What I need from you to give a precise date

1. Country/region: US, EU, UK, Canada, etc.?
2. Do you want the date for:
   • generic competition to start (practical earliest entry), or
   • the date Wegovy-specific patents expire, or
   • the date semaglutide patents expire?

If you tell me your region, I’ll pin down the likely earliest “generic entry” window

Reply with something like: “US” or “EU”, and whether you mean earliest generic entry or patent expiry.